RecruitingNot ApplicableNCT06584448

Drinking, Acetate, and Stress

Role of Acetate in Heavy Drinking


Sponsor

Yale University

Enrollment

50 participants

Start Date

Nov 6, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to learn how drinking alcohol affects how people experience stress and how that is affected by the body's chemistry. Specifically, the investigators will be studying relationships of drinking and a stress hormone called cortisol. The investigators believe that results will lead us to find more effective ways to help people stop or reduce drinking when participants are drinking at harmful levels.


Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This study is investigating how a substance called acetate — which the body produces when it breaks down alcohol — affects stress responses and alcohol cravings in people with alcohol use disorder. Understanding this relationship may help develop better treatments for alcohol dependence. **You may be eligible if...** - You are between 18 and 55 years old - You meet the diagnostic criteria for alcohol use disorder (AUD) - You are medically stable - You can read, write, and complete surveys in English - You are willing to participate in the study's procedures for its duration **You may NOT be eligible if...** - You have serious medical conditions that make participation unsafe - You are pregnant or breastfeeding - You are currently enrolled in another clinical trial - You have a current severe psychiatric condition that may interfere with participation - You are taking certain medications that interact with the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERDeuterium Metabolic Imaging with deuterated acetate tracer

Deuterium Metabolic Imaging (DMI) is a method by which Magnetic Resonance Spectroscopy (MRS) is used to map the appearance of deuterium from a tracer source (e.g., deuterated acetate) in products of metabolism. In this case we will map the combination of glutamate and glutamine, called Glx, to serve as a tag to measure the brain's rate of acetate consumption. That is, the more deuterium appears in Glx, the more acetate that part of the brain consumes.


Locations(2)

The Anlyan Center, 300 Cedar St.

New Haven, Connecticut, United States

Yale University

New Haven, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06584448


Related Trials